Journal article

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

Riccardo Turrini, Anna Merlo, Debora Martorelli, Damiana Antonia Fae, Roberta Sommaggio, Isabella Monia Montagner, Vito Barbieri, Oriano Marin, Paola Zanovello, Riccardo Dolcetti, Antonio Rosato

OncoImmunology | TAYLOR & FRANCIS INC | Published : 2017


The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell origin can benefit from therapeutic mAb targeting specific B-cell lineage antigens. To overcome this limitation, we generated a new mAb specific for BARF1, an EBV-encoded protein with transforming and immune-modulating properties. BARF1 is expressed as a latent protein in nasopharyngeal (NPC) and gastric carcinoma (GC), and also in neoplastic B cells mainly upon lytic cycle induction, thus represe..

View full abstract


Awarded by Italian Association for Cancer Research (AIRC)

Awarded by Special Program Molecular Clinical Oncology 5 per mille

Funding Acknowledgements

This work was partly supported by grants from the Italian Association for Cancer Research ( AIRC, IG-17035 and Special Program Molecular Clinical Oncology 5 per mille ID 10016), and Progetto di Ricerca di Ateneo 2015, University of Padova, to AR.